Cell therapy · developed by Fate Therapeutics
ProTmune is an ex-vivo, programmed cell therapy made from mobilized peripheral blood cells. It is studied in hematologic malignancies, including acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes and chronic myelogenous leukemia, and in acute graft-versus-host disease.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02743351 | Phase 1/2 | Hematologic Malignancies | Completed | FATE |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Acute Graft-versus-host DiseaseAcute Lymphoblastic LeukemiaAcute Myeloid LeukemiaChronic Myelogenous LeukemiaHematologic MalignanciesMyelodysplastic Syndromes
Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.
See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
FATE catalysts and pipeline →